---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015237"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-08-24T23:59:59+00:00"
generated_at: "2026-06-11T04:16:46.465058+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Board Chair Christian Schade resigns; Richard Peters named Chair, Jean-Pierre Bizzari appointed

## Summary
- Christian S. Schade resigned as director and Board Chair on Aug 23, 2023; no disagreement with company.
- Richard Peters, M.D., Ph.D. appointed Board Chair effective immediately after Schade's resignation.
- Dr. Jean-Pierre Bizzari appointed as Class III director through 2025 annual meeting; previously at Celgene and Sanofi.
- Annual meeting: Class I directors Duey, Peters, Seizinger elected (~1.55M for); auditor EisnerAmper LLP ratified (2.05M for).

## SEC filing metadata
- accession: 0001558370-23-015237
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-08-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/0001558370-23-015237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/apre-20230823x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015237
- JSON: https://secwatch.observer/filing/0001558370-23-015237.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015237.txt

## Key facts
- Executive change
  Christian S. Schade resigned as Chairperson of the Board and Director at Aprea Therapeutics, Inc..
  - Action: resigned
  - Role: Chairperson of the Board and Director
  source text: On August 23, 2023, Christian S. Schade resigned from the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”), including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/0001558370-23-015237-index.htm
- Executive change
  Richard Peters was appointed as Chairperson of the Board at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Chairperson of the Board
  source text: Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/0001558370-23-015237-index.htm
- Executive change
  Jean-Pierre Bizzari was appointed as Class III Director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/0001558370-23-015237-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.